Cardiff Oncology, Inc. (CRDF)
NASDAQ: CRDF · Real-Time Price · USD
2.750
+0.090 (3.38%)
At close: May 12, 2025, 4:00 PM
2.840
+0.090 (3.27%)
After-hours: May 12, 2025, 4:08 PM EDT
Cardiff Oncology Revenue
Cardiff Oncology had revenue of $109.00K in the quarter ending March 31, 2025, a decrease of -46.83%. This brings the company's revenue in the last twelve months to $587.00K, down -3.77% year-over-year. In the year 2024, Cardiff Oncology had annual revenue of $683.00K with 39.96% growth.
Revenue (ttm)
$587.00K
Revenue Growth
-3.77%
P/S Ratio
240.68
Revenue / Employee
$17,788
Employees
33
Market Cap
182.95M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 683.00K | 195.00K | 39.96% |
Dec 31, 2023 | 488.00K | 102.00K | 26.42% |
Dec 31, 2022 | 386.00K | 27.00K | 7.52% |
Dec 31, 2021 | 359.00K | -7.00K | -1.91% |
Dec 31, 2020 | 366.00K | 121.37K | 49.61% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
CRDF News
- 4 days ago - Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update - GlobeNewsWire
- 10 days ago - Cardiff Oncology: Expecting Massive Updates In Colon Cancer Soon - Seeking Alpha
- 19 days ago - Cardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve Patients - GlobeNewsWire
- 27 days ago - Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 27 days ago - Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer - GlobeNewsWire
- 2 months ago - Cardiff Oncology, Inc. (CRDF) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Cardiff Oncology to Present at Upcoming Investor Conferences - GlobeNewsWire